Free Trial

Invitae (NVTA) Stock Forecast & Price Target

$0.0028
0.00 (0.00%)
(As of 05/28/2024 ET)

Invitae - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Strong Sell
Based on 2 Analyst Ratings

Consensus Price Target

$1.00
35,614.29% Upside
High Forecast$1.50
Average Forecast$1.00
Low Forecast$0.50
TypeCurrent Forecast
5/30/23 to 5/29/24
1 Month Ago
4/30/23 to 4/29/24
3 Months Ago
3/1/23 to 2/29/24
1 Year Ago
5/30/22 to 5/30/23
Consensus Rating
Strong Sell
Strong Sell
Strong Sell
Reduce
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
6 Hold rating(s)
Sell
2 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
5 Sell rating(s)
Consensus Price Target$1.00$1.00$1.00$3.88
Forecasted Upside35,614.29% Upside19.81% Upside19.81% Upside61.36% Upside
Get Invitae Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

NVTA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVTA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Invitae Stock vs. The Competition

TypeInvitaeMedical CompaniesS&P 500
Consensus Rating Score
1.00
2.70
2.49
Consensus RatingStrong SellModerate BuyHold
Predicted Upside35,614.29% Upside725.03% Upside10.85% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/20/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSell ➝ Sell$1.00 ➝ $0.50-15.15%
8/15/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$1.50+38.89%
5/15/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeMarket Perform ➝ Underperform
11/15/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$2.80-20.45%
11/9/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Souda
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetMarket Perform$2.50 ➝ $3.00+22.95%
11/8/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Brackmann
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
8/24/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderperform
8/10/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight
7/20/2022LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
7/19/2022Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:00 AM ET.

NVTA Frequently Asked Questions

What is Invitae's stock forecast and purchase recommendation?

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Invitae is $1.00, with a high forecast of $1.50 and a low forecast of $0.50. The consensus rating for Invitae stock is Sell based on the current 2 sell ratings for NVTA. Learn more on NVTA's analyst rating history.

Do Wall Street analysts like Invitae more than its competitors?

Analysts like Invitae less than other "medical" companies. The consensus rating for Invitae is Strong Sell while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVTA compares to other companies.

Does Invitae's stock price have much upside?

According to analysts, Invitae's stock has a predicted upside of 19.81% based on their 12-month stock forecasts.


Stock Forecasts and Research Tools

This page (NYSE:NVTA) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners